MiNK Therapeutics will report Q4 2025 financial results on March 31, 2026, and announce clinical updates and collaborations.
Quiver AI Summary
MiNK Therapeutics, Inc. announced that it will release its financial results for the fourth quarter and full year ending December 31, 2025, on March 31, 2026, before the market opens, followed by a conference call at 8:30 a.m. ET for updates on its iNKT cell therapy portfolio and corporate developments. The company recently formed a collaboration with C-Further and the University of Southampton to develop a PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers, which brings non-dilutive funding and significant commercial potential. This partnership highlights MiNK's strategy to expand its iNKT platform through clinical programs and partnerships to enhance capital efficiency. The company focuses on developing innovative therapies, including their lead candidate, agenT-797, aimed at treating various immune-related conditions and cancers.
Potential Positives
- MiNK Therapeutics announced a collaboration with C-Further and the University of Southampton to advance a PRAME-targeted iNKT cell therapy for pediatric cancers, indicating strong strategic partnerships.
- The collaboration provides non-dilutive funding, which can enhance financial stability and reduce reliance on equity financing.
- This program further validates MiNK's iNKT platform in engineered cell therapy, highlighting its innovative approach and competitive positioning in the biopharmaceutical market.
- MiNK's pipeline includes therapies that address various serious conditions, demonstrating a broad therapeutic potential and commitment to addressing significant unmet medical needs.
Potential Negatives
- The press release heavily emphasizes upcoming financial results and collaborations but lacks disclosure of specific financial metrics or prior performance, which may raise concerns regarding transparency and financial health.
- While announcing a collaboration, the release does not indicate the potential competitive landscape or how it might affect MiNK's market position, leaving investors uncertain about strategic advantages.
- The mention of risks and uncertainties associated with forward-looking statements without providing further context may lead to investor skepticism and concern regarding the company's future performance.
FAQ
When will MiNK Therapeutics report its financial results?
MiNK Therapeutics will report its financial results for Q4 and the full year on March 31, 2026.
What is the purpose of the upcoming conference call?
The conference call will review financial results and provide corporate updates on clinical progress and strategic initiatives.
What is the significance of the collaboration with C-Further?
The collaboration aims to advance a PRAME-targeted iNKT cell therapy for pediatric cancers, enhancing MiNK’s iNKT platform.
How does MiNK's iNKT platform benefit cancer treatments?
MiNK’s iNKT platform bridges innate and adaptive immunity to address various cancers and immune disorders effectively.
Where can I access the conference call replay?
The conference call replay will be available on the Events & Presentations page of MiNK's website.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$INKT Insider Trading Activity
$INKT insiders have traded $INKT stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $INKT stock by insiders over the last 6 months:
- BARBARA RYAN has made 0 purchases and 6 sales selling 2,000 shares for an estimated $27,477.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$INKT Hedge Fund Activity
We have seen 9 institutional investors add shares of $INKT stock to their portfolio, and 7 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC added 34,300 shares (+102.8%) to their portfolio in Q4 2025, for an estimated $382,445
- DRW SECURITIES, LLC added 25,677 shares (+inf%) to their portfolio in Q4 2025, for an estimated $286,298
- NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO added 7,755 shares (+40815.8%) to their portfolio in Q4 2025, for an estimated $86,468
- RENAISSANCE TECHNOLOGIES LLC removed 4,200 shares (-28.8%) from their portfolio in Q4 2025, for an estimated $46,830
- UBS GROUP AG added 3,900 shares (+69.1%) to their portfolio in Q4 2025, for an estimated $43,485
- GEODE CAPITAL MANAGEMENT, LLC added 1,441 shares (+11.3%) to their portfolio in Q4 2025, for an estimated $16,067
- TOWER RESEARCH CAPITAL LLC (TRC) removed 631 shares (-68.1%) from their portfolio in Q4 2025, for an estimated $7,035
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Tuesday, March 31, 2026.
The company will host a conference call and webcast at 8:30 a.m. ET that morning to review financial results and provide a corporate update on clinical progress, platform expansion, and strategic initiatives across its iNKT cell therapy portfolio.
The update follows several recent corporate and development milestones, including MiNK’s newly announced collaboration with C-Further and the University of Southampton to advance a PRAME-targeted, TCR-engineered iNKT cell therapy for pediatric cancers. The collaboration brings non-dilutive funding, meaningful downstream commercial revenue potential, and further validation of MiNK’s iNKT platform in engineered cell therapy. The program expands MiNK’s presence across validated tumor antigens and underscores the broader therapeutic and strategic value of its clinically advanced, allogeneic iNKT platform.
The collaboration reflects MiNK’s strategy of expanding its iNKT platform across both clinical-stage programs and engineered cell therapy approaches targeting validated tumor antigens, while leveraging external partnerships to advance programs in a capital-efficient manner.
| Conference Participant Dial Information | |
| United States - New York | (646) 307-1963 |
| USA & Canada - Toll-Free | (800) 715-9871 |
| Conference ID - | 6761941 |
Webcast & Replay Information
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website following the event.
Live event link:
https://edge.media-server.com/mmc/p/6xxeh8o5
Webcast Replay:
https://investor.minktherapeutics.com/events-and-presentations
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies and precision immune modulators designed to restore immune balance and drive durable cytotoxic responses. MiNK’s proprietary iNKT platform bridges innate and adaptive immunity to address cancer, autoimmune disease, and immune collapse.
Its lead candidate, agenT-797, is an off-the-shelf, cryopreserved iNKT cell therapy currently in clinical trials for solid tumors, graft-versus-host disease (GvHD), and critical pulmonary immune failure. MiNK’s pipeline also includes TCR-based and neoantigen-targeted iNKT programs that enable tissue-specific immune activation. With a scalable manufacturing process and broad therapeutic potential, MiNK is advancing a new class of immune reconstitution therapies designed to deliver durable, accessible, and globally deployable treatments.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the potential, safety, clinical benefit, and development plans for agenT-797 and other iNKT-based therapies. These statements involve risks and uncertainties, including those described under “Risk Factors” in MiNK’s most recent SEC filings. MiNK undertakes no obligation to update these statements except as required by law.
Contacts
Investor Contact: 917-362-1370 |
[email protected]
Media Contact: 781-674-4428 |
[email protected]
Source: MiNK Therapeutics
